Login
$CERT
$11.39 -$0.18 (1.56%) Live

$CERT 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Certara delivers a solid quarter with double-digit software revenue growth

07 Aug 2026 8-K: Regulation FD Disclosure

On August 4, 2026, Certara, Inc. (the “Company”) hosted its second quarter 2026 earnings conference call and posted on its website its second quarter 2026 earnings presentation. On the earnings conference call, there was a misstatement i...

04 Aug 2026 8-K: Results of Operations and Financial Condition

Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program

04 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

On August 4, 2026, Certara, Inc. (the “Company”) announced the departure of Leif E. Pedersen from his role as the Company’s President, Chief Commercial Officer, effective as of August 1, 2026. The Company intends to retain Mr. Pedersen a...

17 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

RADNOR, PA – June 17, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effe...

15 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 14, 2026, Certara, Inc. (the “Company”) held its annual meeting of stockholders. The proposals are described in the Company’s proxy statement for the 2026 Annual Meeting of Stockholders filed with the Securities and Exchange Commi...

11 May 2026 8-K: Results of Operations and Financial Condition; Other Events

Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business

22 Apr 2026 8-K: Entry into a Material Definitive Agreement

Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence

31 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

26 Feb 2026 8-K: Results of Operations and Financial Condition

FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth)

11 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth

06 Nov 2025 8-K: Results of Operations and Financial Condition

RADNOR, PA— November 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025.

16 Oct 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

SIXTH AMENDMENT, dated as of October 16, 2025 (this “Agreement”), to the Credit Agreement dated as of August 15, 2017 (as amended by the First Amendment thereto, dated as of January 24, 2018, by the Second Amendment thereto, dated as of ...

06 Aug 2025 8-K: Results of Operations and Financial Condition

RADNOR, PA— August 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025.

22 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 21, 2025, Certara, Inc. (the “Company”) held its annual meeting of stockholders. The proposals are described in the Company’s proxy statement for the 2025 Annual Meeting of Stockholders filed with the Securities and Exchange Commi...

05 May 2025 8-K: Results of Operations and Financial Condition

RADNOR, PA— May 5, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025.

14 Apr 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

RADNOR, PA — April 14, 2025 - Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter ...

05 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

On March 5, 2025, Certara, Inc. (the “Company”) announced that Dr. Patrick F. Smith, President, Certara Drug Development Solutions, stepped down from that role as of March 3, 2025, but will remain employed by the Company in a senior advi...

26 Feb 2025 8-K: Results of Operations and Financial Condition

RADNOR, PA - February 26, 2025 - Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024.

15 Jan 2025 8-K: Results of Operations and Financial Condition

Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support